Recruiting
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA
I4V-MC-JAHU - ClinicalTrials.gov - NCT04088396
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA).
How long will I be in the trial?
The study will last about 164 weeks and may include up to 30 visits.
Recruiting
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA
I4V-MC-JAHU - ClinicalTrials.gov - NCT04088396
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA).
How long will I be in the trial?
The study will last about 164 weeks and may include up to 30 visits.
Key Requirements
Age :
1-17
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
1-17
Sex
All
Participants must
Participants must have systemic Juvenile Idiopathic Arthritis (sJIA) with onset before the age of 16 years
Participants must have arthritis in a joint and fever lasting 2 weeks, with daily fever for 3 days, and at least 1 of the following: Evanescent erythematous rash, generalized lymph node enlargement, enlarged liver/spleen, serositis
Participants must have at least 2 active joints
Participants must NOT
Participants must not have polyarticular JIA, extended oligoarticular JIA, enthesitis-related JIA or juvenile psoriatic arthritis
Participants must not have persistent oligoarticular arthritis
Participants must not have any autoimmune inflammatory condition other than JIA
Participants must not have active anterior uveitis
Participants must not have active fibromyalgia or other chronic pain conditions
Participants must not have an infection
Participants must not have hepatitis B or tuberculosis (TB)
Trial Summary
Conditions the trial is for
Systemic Juvenile Idiopathic Arthritis
What the trial is testing?
Baricitinib, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
103
Trial Dates
February 2020 - August 2023
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
1-17
Sex
All
Participants must
Participants must have systemic Juvenile Idiopathic Arthritis (sJIA) with onset before the age of 16 years
Participants must have arthritis in a joint and fever lasting 2 weeks, with daily fever for 3 days, and at least 1 of the following: Evanescent erythematous rash, generalized lymph node enlargement, enlarged liver/spleen, serositis
Participants must have at least 2 active joints
Participants must NOT
Participants must not have polyarticular JIA, extended oligoarticular JIA, enthesitis-related JIA or juvenile psoriatic arthritis
Participants must not have persistent oligoarticular arthritis
Participants must not have any autoimmune inflammatory condition other than JIA
Participants must not have active anterior uveitis
Participants must not have active fibromyalgia or other chronic pain conditions
Participants must not have an infection
Participants must not have hepatitis B or tuberculosis (TB)
Trial Summary
Conditions the trial is for
Systemic Juvenile Idiopathic Arthritis
What the trial is testing?
Baricitinib, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
103
Trial Dates
February 2020 - August 2023
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Systemic Juvenile Idiopathic Arthritis Resources
